Verve Therapeutics said Monday that initial data show that its investigational gene-editing therapy lowered cholesterol ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Verve Therapeutics (NASDAQ:VERV) shares climbed ~23% in the premarket on Monday after the company said its gene editing ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...

The results show dose-dependent LDL-lowering and, in contrast to what was seen previously with VERVE-101, no safety issues.

A phase 1b showed promising results in lowering LDL in patients with heterozygous familial hypercholesterolemia and/or ...

VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Click here to find out why I rate VERV ...